Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2025.11.014 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Alper Türkel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dr.Abdurrahman Yurtaslan Ankara Oncology Research and Treatment Hospital, Ankara, Turkey. Electronic address: turkela…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoplasm Recurrence, Local, Ado-Trastuzumab Emtansine. Die Arbeit nennt 22 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: This study aimed to investigate the survival outcomes of adjuvant trastuzumab emtansine (T-DM1) in patients with early-stage HER2-positive breast cancer and the recurrence patterns in those who experienced recurrence. METHODS: This multicenter, retrospective study included 121 patients with early-stage HER2-positive breast cancer who underwent surgery following neoadjuvant chemotherapy and anti-HER2 therapy and received adjuvant T-DM1 for residual disease. Recurrence within the first 12 months of adjuvant T-DM1 was defined as ``early recurrence,'' while recurrence after 12 months (> 12 months) was defined as ``late recurrence.' ' RESULTS: With a median follow-up of 36 months, recurrence occurred in 23 patients (median time: 11 months). Twenty-two had distant metastases-most commonly lung (n = 14) and CNS (n = 6)-and one had local recurrence. The recurrent subgroup had higher Ki67, tumor grade, and HR-negativity rate (P = .015, P = .034, and P = .014, respectively). Among recurrences, 12 were early (≤ 12 months) and 11 were late recurrence (> 12 months). Patients with early recurrence were significantly younger (P = .007) and had a numerically higher median Ki67 (40% vs. 30%, P = .062). DFS rates at 12, 24, and 36 months were 93.3%, 75.2%, and 62.8%, respectively; OS rates were 100%, 98.3%, and 93.1%. CONCLUSIONS: Younger patients with HR-negative, high-grade, high Ki67 tumors had significantly higher rates of recurrence. Defining patient subpopulations through biomarker identification is crucial for tailoring escalation and de-escalation strategies, thereby enabling more effective treatments and improved long-term survival. The mechanisms of T-DM1 resistance require investigation through larger trials and molecular profiling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dr.Abdurrahman Yurtaslan Ankara Oncology Research and Treatment Hospital, Ankara, Turkey. Electronic address: turkelalperr@gmail.com.
- Department of Medical Oncology, Dr.Abdurrahman Yurtaslan Ankara Oncology Research and Treatment Hospital, Ankara, Turkey.
- Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.
- Department of Medical Oncology, Aydın Adnan Menderes University, Aydın, Turkey.
- Department of Medical Oncology, Manisa Celal Bayar University, Manisa, Turkey.
- Department of Medical Oncology, Muğla Sıtkı Koçman University, Muğla, Turkey.
Zitieren
APA
Türkel, A., Onur, İ. D., Karakayalı, A., Alemdar, M. B., Türkmen, E., Alkan, A., Yıldız, S., Majidova, N., Emin, G., Gürbüz, A. F., Şahin, E., Şakalar, T., Yalıcı, Ö., Erdoğan, A. P., Coşar, R., Karaman, E., Eryılmaz, M. K., & Doğan, M. (2026). Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.11.014
Vancouver
Türkel A, Onur İD, Karakayalı A, Alemdar MB, Türkmen E, Alkan A, et al. Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.11.014
BibTeX
@article{Trkel2026,
author = {Türkel, Alper and Onur, İlknur Deliktaş and Karakayalı, Anıl and Alemdar, Merve Bıyıklı and Türkmen, Emine and Alkan, Ali and Yıldız, Sedat and Majidova, Nargiz and Emin, Gamze and Gürbüz, Ali Fuat and Şahin, Elif and Şakalar, Teoman and Yalıcı, Özge and Erdoğan, Atike Pınar and Coşar, Ramazan and Karaman, Elanur and Eryılmaz, Melek Karakurt and Doğan, Mutlu},
title = {Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2025.11.014}
}
EUVIMED